EXCLUSIVE SUBLICENSE AGREEMENTExclusive Sublicense Agreement • March 27th, 2007 • Biosante Pharmaceuticals Inc • Biological products, (no disgnostic substances) • Illinois
This AGREEMENT (“Agreement”), dated November 7, 2006 (the “Effective Date”), is made by and between BioSante Pharmaceuticals, Inc., 111 Barclay Boulevard, Lincolnshire, IL 60069 (“BPA”), and Bradley Pharmaceuticals, Inc., 383 Route 46 West, Fairfield, New Jersey 07004-2402 (“Company”).
CONFIDENTIALEmployment Agreement • March 27th, 2007 • Biosante Pharmaceuticals Inc • Biological products, (no disgnostic substances) • Illinois
THIRD AMENDMENT TO LEASELease • March 27th, 2007 • Biosante Pharmaceuticals Inc • Biological products, (no disgnostic substances)
THIS AMENDMENT, Made and entered into as of the 14th day of August, 2006, by and between Highlands Park Associates, Landlord, and BioSante Pharmaceuticals, Inc., Tenant.
Amendment No. 6 to the License Agreement dated 13th of June 2000 by and between Antares Pharma IPL AG, Zug, Switzerland as Licensor (formerly known as Permatec Technologies AG) and BioSante Pharmaceuticals, Inc., Lincolnshire, IL, USA as LicenseeLicense Agreement • March 27th, 2007 • Biosante Pharmaceuticals Inc • Biological products, (no disgnostic substances)
WHEREAS, Antares Pharma IPL AG, Zug, Switzerland (“Antares”) and BioSante Pharmaceuticals, Inc., Lincolnshire, Illinois, United States of America (“BioSante”) have previously entered into a License Agreement dated June 13, 2000 (“License Agreement”), as amended in a series of five amendments, as follows: Amendment No. 1, dated May 20, 2001; Amendment No. 2, dated July 5, 2001; Amendment No. 3, dated August 30, 2001; Amendment No. 4, dated August 8, 2002; and Amendment No. 5, dated December 30, 2002 (collectively the Amendments and with the License Agreement, the “Agreement”); and
